Biotron Limited (AU:BIT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Biotron Limited reported mixed results from its Phase 2 COVID-19 trial for the antiviral drug BIT225, which met safety and tolerability endpoints but not efficacy targets. Despite this, Biotron continues to advance its research on antiviral compounds, including promising developments in HIV-1 and Dengue virus programs. The company remains committed to exploring commercial opportunities for its unique viroporin antagonist platform, which shows broad-spectrum antiviral activity.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.